NCT05737706View on ClinicalTrials.gov

Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

PHASE1TerminatedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

March 6, 2023

Primary Completion Date

March 10, 2025

Study Completion Date

March 10, 2025

Conditions
Solid TumorAdvanced Solid TumorNon-small Cell Lung CancerColo-rectal CancerPancreatic Adenocarcinoma
Interventions
DRUG

MRTX1133

KRAS G12D Inhibitor

Trial Locations (14)

21231

Local Institution - 306, Baltimore

22031

Local Institution - 305, Fairfax

37203

Local Institution - 303, Nashville

49546

Local Institution - 314, Grand Rapids

77030

Local Institution - 302, Houston

78229

Local Institution - 313, San Antonio

85054

Local Institution - 311, Phoenix

06520 8028

Local Institution - 309, New Haven

32159 8987

Local Institution - 301, Lady Lake

02114 3117

Local Institution - 308, Boston

02215

Local Institution - 310, Boston

10065 6800

Local Institution - 312, New York

78229 3307

Local Institution - 304, San Antonio

98109 1023

Local Institution - 307, Seattle

Sponsors
All Listed Sponsors
lead

Mirati Therapeutics Inc.

INDUSTRY

NCT05737706 - Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation | Biotech Hunter | Biotech Hunter